Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritisAppointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business OfficerCash, cash equivalents and marketable securities totaled $306.8 million as of June 30, 2022SOUTH SAN FRANCISC.
Stock Market | Daily Herald dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Mallinckrodt plc (OTCMKTS: MNKPF), a global biopharmaceutical company, today announced two scientific posters to be presented on the disease.
Data being presented at the CMSC Annual Meeting demonstrates UPLIZNA may reduce attack risk and disability among populations with genetic variables typically linked to poor treatment response
In clinical trials, RINVOQ (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score [mMS]) at weeks 8 and 521-4 A greater.